PMV Pharmaceuticals (PMV Pharmaceuticals) Total Equity : $212.68 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is PMV Pharmaceuticals Total Equity?

PMV Pharmaceuticals's total equity for the quarter that ended in Mar. 2024 was $212.68 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

PMV Pharmaceuticals Total Equity Historical Data

The historical data trend for PMV Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PMV Pharmaceuticals Total Equity Chart

PMV Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Equity

Get a 7-Day Free Trial

-70.47

359.12

308.56

246.03

225.69

PMV Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Equity	Get a 7-Day Free Trial															230.17	217.81	237.61	225.69	212.68

PMV Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

PMV Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	252.152	-	26.463
	=	225.69

PMV Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity	=	Total Assets(Q: Mar. 2024 )	-	Total Liabilities(Q: Mar. 2024 )
	=	236.876	-	24.2
	=	212.68

PMV Pharmaceuticals Total Equity Related Terms

Thank you for viewing the detailed overview of PMV Pharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

PMV Pharmaceuticals (PMV Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PMV Pharmaceuticals Inc (NAS:PMVP) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Research Way, Princeton, NJ, USA, 08536

Website

https://www.pmvpharma.com

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.

Executives

Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Leila Alland	officer: Chief Medical Officer	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Deepika Jalota	officer: SVP, Regulatory Affairs and QA	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Carol Giltner Gallagher	director	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Orbimed Capital Gp V Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kirsten Flowers	director	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Thilo Schroeder	director, 10 percent owner	C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Arnold J Levine	director	C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Winston Kung	officer: COO, CFO	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
David Henry Mack	director, officer: President and CEO	ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Euclidean Capital Llc	10 percent owner	160 FIFTH AVE, 9TH FL, NEW YORK NY 10010
James H Simons	10 percent owner	RENAISSANCE TECHNOLOGIES LLC, 800 THIRD AVE, NEW YORK NY 10022
Greenland A Llc	10 percent owner	C/O EUCLIDEAN CAPITAL LLC, 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010